CNMD

$37.34

Post-MarketAs of Mar 17, 8:00 PM UTC

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$37.34
Potential Downside
23.4%
Whystock Fair Value$28.60
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.16B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.73
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Strong income play. Yield provides a meaningful total return floor.
214.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
4.71%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.92

Recent News

The Fly
Mar 17, 2026

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 12, 2026

A Look At CONMED (CNMD) Valuation After Recent Weak Share Price Momentum

CONMED (CNMD) has been on some investors’ radars after recent share performance, with the stock showing negative returns over the past month and past 3 months. This has prompted closer attention to its current valuation. See our latest analysis for CONMED. At a share price of $38.40, CONMED’s recent 7 day share price return of 10.68% decline and year to date share price return of 5.23% decline sit alongside a 1 year total shareholder return of 34.34% decline. Together, these moves point to...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 10, 2026

3 Stocks Under $50 with Open Questions

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 10, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 6, 2026

PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.